The best stocks to watch tomorrow are not the ones every headline is chasing. Meta, Tesla and SpaceX dominated Wednesday, but the sharper setups for Thursday, Oct. 22 are in the mid-caps and micro-caps: Bloom Energy and MaxLinear report after the close, NVE Corp and Hexcel are gapping down on earnings, QuantumScape is gapping up, and a trio of small caps ripped on news and crypto momentum. Here are ten under-the-radar stocks to watch tomorrow, each with a full data table, support and resistance, a bull and bear case, and a forecast.
Today’s Market Snapshot: Nasdaq Leads a Third Straight Rally, Then Futures Slip
| Index / Asset | Wednesday, Oct. 21 Close | Day | Week | Year to Date |
|---|---|---|---|---|
| S&P 500 | 7,757.17 | +0.58% | +1.3% | +13.3% |
| Dow Jones Industrial Average | 52,856.09 | +0.69% (+360 points) | +1.6% | +10.0% |
| Nasdaq Composite | 26,702.86 | +1.05% | +2.2% | +14.9% |
| Russell 2000 | n/v | n/v | About +2.2% | n/v |
| Philadelphia Semiconductor Index | n/v | Nearly +2% | n/v | n/v |
The S&P 500 notched a three-day winning streak as SpaceX jumped about 7.8% and chip stocks snapped an eight-session losing streak, per TradingKey’s recap. After the close, futures fell about 0.5% as Meta rose 2% to 3% and Tesla and Lam Research slid. Bitcoin climbed to about $84,700, and Brent crossed $110 per a Stocktwits roundup.
Macro drivers for Thursday:
- Big after-hours moves: Meta guided Q4 revenue to $73B to $76B and floated a 2-for-1 split, while Tesla slipped after its report. Lam Research fell about 5% after hours.
- Earnings wave: 215 companies report Thursday, including Procter & Gamble, Valero, Union Pacific, Lockheed Martin and Spotify before the open, and Intel, Western Digital, Newmont, First Solar and Bloom Energy after the close.
- Rates: The 10-year yield is near 5.11% with the Fed meeting Oct. 27-28. See TNN’s October Fed rate hike explainer.
Data note: Closes are Oct. 21 official prints from StockAnalysis, Finviz, Yahoo Finance or MarketBeat where stated. Derived or intraday figures (MaxLinear, Hexcel, QuantumScape, Cypherpunk, American Bitcoin, Tenax) are labeled. After-hours prices move quickly and are shown as ranges. Support and resistance levels are analytical zones, not guarantees. “n/v” means not verified.
1. Bloom Energy (BE) | Earnings After the Bell | Closed $238.53 (+7.13%)
Musk, Oracle and a 10% Options Bet: The AI Power Stock Reports Thursday
Catalyst & latest news: Bloom reports Q3 on Oct. 22 after the close, with a call at 5:00 p.m. ET. Consensus is about $0.67 to $0.71 a share on $1.05B to $1.07B of revenue, roughly double last year, and options imply a 9% to 12% move. The stock jumped 7% Wednesday after Elon Musk said power and cooling, not chips, are the main limits on AI expansion and Oracle said its Project Jupiter campus is moving quickly. TNN covered the AI-infrastructure backdrop in its IREN forecast.
Technicals: BE gapped up at $235.36, ranged $229.30 to $243 on 12.2M shares (versus a 13.0M average) and slipped about 2% after hours. Schaeffer’s noted a 14-day RSI near 27 and 200-day support near $218 before the bounce.
Fundamentals: Q2 revenue was $1.065B (+165.5%) with EPS of $0.78 versus $0.40 expected. Management lifted 2026 guidance to $3.9B to $4.2B in revenue and $2.55 to $2.85 in EPS, and Bloom has beaten EPS estimates four quarters in a row.
| Metric | Data |
|---|---|
| Last close / prior close | $238.53 (+$15.88, +7.13%) / $222.65 |
| Day’s range | $229.30 – $243 |
| After-hours | $233.68 – $234.05 (about -2%) |
| 52-week range | $75.70 – $351.28 |
| Market cap | About $56B (derived) |
| P/E (TTM) / Dividend | About 266 / None |
| Volume vs. average | 12.2M vs. 13.0M (-6%) |
| Performance | YTD about +175%; about 32% below the 52-week high |
| Beta | 3.78 |
| Q3 estimates | EPS about $0.67 – $0.71; revenue about $1.05B – $1.07B (+106%) |
| Analysts | Moderate Buy (10 Buy, 8 Hold); targets $261 – $301; UBS $350, Baird $351, Truist Hold $240 |
| Next earnings | Oct. 22 after close (implied move 9% – 12%) |
| Support (S1 / S2 / S3) | $229.30 / $222.65 / $218 |
| Resistance (R1 / R2 / R3) | $243 / $249 (50-day) / $290 |
Scenarios:
Bullish: a beat and higher backlog push through $249 toward $290. Base: a 9% to 12% move either direction. Bearish: a guidance wobble loses $222.65 and tests the 200-day near $218.
Bull case: Triple-digit growth, raised guidance, marquee customers (Oracle, Nebius, Brookfield) and a power-bottleneck narrative. Bear case: A 266x trailing P/E, a beta near 4, insider selling at $277 and a stock that already ran 7% into the print.
What to watch:
- Backlog and bookings versus revenue growth
- Any change to the $3.9B to $4.2B revenue guide
- Updates on Oracle’s Project Jupiter and customer concentration
Forecast: A clean beat targets $249 to $290. A miss or cautious guide likely tests $218 to $222.
Why this matters: Bloom is the purest listed bet on AI power demand, so its print will move fuel-cell peers and the broader AI-infrastructure trade.
2. MaxLinear (MXL) | Earnings After the Bell | Reading $75.79 (+3.1%)
The Optical-Chip Rocket Now Priced at 12x Sales Into Its Own Report
Catalyst & latest news: MaxLinear reports Q3 on Oct. 22 after the close, with a 4:30 p.m. ET call. Analysts expect $0.56 in EPS on $210M to $215M of revenue, up about 66%, in line with its $210M to $220M guide. StoneX reiterated Buy with a $125 target and expects $227.5M in Q4 revenue.
Technicals: GuruFocus showed MXL up 3.1% to $75.79 on Oct. 21, sitting between its 200-day ($73.22 to $74.48) and 50-day ($77.17 to $77.48) averages. The stock fell 9.5% on Oct. 14 from $88.64 and is far below its $128.30 high.
Fundamentals: Q2 revenue was $168.85M (+55.2%) with EPS of $0.35 versus $0.33. Infrastructure revenue grew 141% in the first half, and the company raised its 2026 optical data-center revenue target to $210M to $230M. Net margin is still negative at about 18%.
| Metric | Data |
|---|---|
| Last reading / prior close | $75.79 (+3.1%, GuruFocus Oct. 21; official close n/v) / about $73.5 (derived) |
| 52-week range | $12.77 – $128.30 |
| Market cap | About $7.0B (derived) |
| P/E / Dividend | Negative (about -66) / None |
| Price-to-sales | About 12x (median 3.8x) |
| Volume vs. average | n/v / about 3.1M |
| Performance | About +335% over one year; about 41% below the high |
| Beta | 3.93 |
| Q3 estimates | EPS about $0.56; revenue $210M – $215M (+66%) |
| Analysts | Hold (5 Buy, 3 Hold, 1 Sell); average target $88.64; StoneX $125; Stifel $120 |
| Insider activity | CEO sold 351,454 shares (about $30.2M) |
| Next earnings | Oct. 22 after close |
| Support (S1 / S2 / S3) | $73.22 / $71.32 / $65 |
| Resistance (R1 / R2 / R3) | $77.17 / $80.18 / $88.64 |
Scenarios:
Bullish: a beat and Q4 guide near $227M reclaims $88. Base: a large, two-way move around the 50-day. Bearish: a sales miss loses $71.32 and targets $65.
Bull case: Optical and AI data-center demand, a Buy-rated target near $125 and accelerating infrastructure sales. Bear case: A 12x sales multiple, GuruFocus’ fair value near $21, heavy insider selling and a 3.9 beta.
What to watch:
- Q4 revenue guide versus $226M to $228M
- Optical data-center revenue commentary
- Gross margin trend
Forecast: A beat targets $77 to $88. A weak guide likely loses $71 and heads toward $65.
Why this matters: MaxLinear is a high-beta read on the AI-optical supply chain, a theme that also drove Micron and Nvidia.
3. Hexcel (HXL) | Revenue Miss, Down 10% After Hours | Closed About $89.84 (-1.58%)
The Boeing and Airbus Supplier Gets Hit Even as Aerospace Sales Climb
Catalyst & latest news: Hexcel posted adjusted EPS of $0.50 versus $0.49 expected but revenue of $496.4M missed the $500M to $502M consensus. It held guidance, and Seeking Alpha reported the stock down 10% after hours. Investing.com noted the $2.35 EPS guide midpoint sits below the $2.40 consensus. The company raised its buyback authorization to $750M.
Technicals: HXL fell 1.6% to about $89.84 on 1.73M shares versus a 1.09M average, then traded between about $79.82 and $82.20 after hours. It has a 52-week range of $63.21 to $111.74.
Fundamentals: Sales rose 8.8% to $496.4M, gross margin hit 23.3% (21.9% a year ago) and operating income reached $54.8M. The release shows 2026 guidance of $2.025B to $2.125B in sales and $2.30 to $2.40 in EPS, with free cash flow above $195M. Free cash flow margin fell to 10.2% from 21.2%.
| Metric | Data |
|---|---|
| Last close / prior close | About $89.84 (-1.58%) / about $91.32 |
| After-hours | About $79.82 – $82.20 (-8.5% to -11.2%) |
| 52-week range | $63.21 – $111.74 |
| Market cap | About $7.8B (derived; $6.9B at the after-hours price) |
| P/E (TTM) / Dividend | 45.3 / n/v |
| Volume vs. average | 1.73M vs. 1.09M (+59%) |
| Q3 EPS / revenue | $0.50 vs. $0.49 est. / $496.4M (+8.8%) vs. about $501M est. |
| 2026 guidance | Sales $2.025B – $2.125B; EPS $2.30 – $2.40; FCF above $195M |
| Analysts | Hold (1 Strong Buy, 5 Buy, 9 Hold, 1 Sell); average target $103.25 |
| Fair value | GF Value $84 |
| Support (S1 / S2 / S3) | $79.82 / $75 / $63.21 |
| Resistance (R1 / R2 / R3) | $89.84 / $91.32 / $97 |
Scenarios:
Bullish: buyback buyers reclaim $89.84. Base: a gap to $80 to $84 and basing. Bearish: a break of $79.82 heads to $75.
Bull case: Commercial aerospace growth, margin expansion and a bigger buyback. Bear case: A revenue miss, weak defense and space sales, and a stock that was above its fair value before the drop.
What to watch:
- The opening gap against the $79.82 after-hours low
- Analyst target cuts on Thursday
- Boeing and Airbus build-rate commentary
Forecast: Holding $79.82 allows a bounce to $84 to $89. A break targets $75.
Why this matters: Hexcel is a supplier-chain read for Boeing’s Oct. 27 report and for aerospace demand generally.
4. NVE Corp (NVEC) | Earnings Wipeout After the Bell | Closed $103.07 (+1.00%)
A 41-Employee Chip Maker Down 19% After Hours as Defense Sales Fall 95%
Catalyst & latest news: NVE reported fiscal Q2 EPS of $0.65 versus $0.68 a year ago on $5.58M of revenue, down about 8%, because defense product sales fell 95% and some medical orders were pulled into the prior quarter. The stock closed at $103.07, then traded as low as $81.27, down 18.7% to 21.2% after the call.
Technicals: NVEC rose 1.0% from $102.05 into the print and had traded in a $57.21 to $135 range over 52 weeks. After-hours prices of $81 to $84 sit well below its prior support near $100. GuruFocus lists a 2-month average volume near 230K shares.
Fundamentals: First-half revenue was $16.87M, up 36%, with distributor sales up 67%. Management said net margin was 54%, gross margin 78% and operating margin 55%, with cash and securities of $44.4M. The $1.00 quarterly dividend is payable Nov. 30, and NVE launched wafer-level sensors aimed at robotics.
| Metric | Data |
|---|---|
| Last close / prior close | $103.07 (+$1.02, +1.00%) / $102.05 |
| After-hours | About $81.27 – $83.76 (-18.7% to -21.2%) |
| 52-week range | $57.21 – $135 |
| Market cap | About $498M at the close (derived, 4.84M shares); about $400M after hours |
| P/E (TTM) / Dividend | 27.1 / $4.00 a year (3.9% at close; about 4.9% at $82) |
| Volume vs. average | n/v / about 230K (2-month) |
| Beta | 1.34 |
| Q2 EPS / revenue | $0.65 vs. $0.68 a year ago / $5.58M (-8%) |
| First-half revenue / net income | $16.87M (+36%) / $9.57M ($1.97 per share) |
| Cash and securities | $44.4M; current ratio about 23.7 |
| Analysts | n/v (very limited coverage) |
| Support (S1 / S2 / S3) | $81.27 / $75 / $57.21 |
| Resistance (R1 / R2 / R3) | $90 / $102.05 / $103.07 |
Scenarios:
Bullish: dividend and cash buyers push the stock back above $90. Base: a gap to $82 to $88 and basing. Bearish: a break of $81 targets $75.
Bull case: A net margin above 50%, a growing dividend and large cash against a $400M to $500M value. Bear case: Lumpy defense sales, a revenue decline and a very small, thinly traded stock.
What to watch:
- Whether the opening gap holds above $81.27
- Any defense order commentary
- Insider or buyback activity after the drop
Forecast: Holding $81 allows a bounce toward $90. A break likely tests $75.
Why this matters: NVEC shows how a small, high-margin chip company can swing 20% on one quarter’s order timing, even with half-year growth of 36%.
5. QuantumScape (QS) | Beats Loss Estimate, Up 12% After Hours | Close About $3.98 (derived)
$820 Million of Liquidity, Zero Revenue and a New Data Center Battery Product
Catalyst & latest news: QuantumScape reported a Q3 GAAP loss of $0.14 a share versus $0.17 expected, and Benzinga lists the stock up 12.1% to $4.46 after hours, which implies a regular close near $3.98. Management said it began generating customer billings from QSE-5 sample shipments, announced the QS PowerBlock for data centers and reiterated its 2026 guidance.
Technicals: QS has no revenue, so the stock trades on milestones. Its market value was about $2.46B on Oct. 20, per GuruFocus, and the after-hours price of $4.46 sits near a round-number resistance at $4.50.
Fundamentals: The Q3 letter shows a GAAP net loss of $84.5M, operating expenses of $92.4M, an adjusted EBITDA loss of $60.7M and capex of $4.4M. Customer billings were $9.8M, and liquidity was $819.8M. Full-year adjusted EBITDA loss guidance is $250M to $275M.
| Metric | Data |
|---|---|
| Last close (derived) / prior close | About $3.98 / n/v |
| After-hours | $4.46 (+12.1%) |
| 52-week range / day range | n/v / n/v |
| Market cap | About $2.2B – $2.5B |
| P/E / Dividend | n/a (pre-revenue) / None |
| Volume vs. average | n/v |
| Q3 EPS | -$0.14 vs. -$0.17 est. |
| Q3 net loss / adj. EBITDA loss | $84.5M / $60.7M |
| Liquidity / billings | $819.8M / $9.8M |
| 2026 guidance | Adj. EBITDA loss $250M – $275M |
| Analysts | n/v; GF Score 33/100 |
| Support (S1 / S2 / S3) | $3.98 / $3.60 / $3.20 |
| Resistance (R1 / R2 / R3) | $4.46 / $4.75 / $5.00 |
Scenarios:
Bullish: a gap above $4.46 on holding buyers targets $4.75. Base: a gap-and-fade between $4.00 and $4.50. Bearish: a failed gap loses $3.98 and tests $3.60. Support and resistance here are round-number zones because verified daily data was limited.
Bull case: A big cash cushion, defense and AI data center product lines and a 2030 target market of $75B. Bear case: No meaningful revenue, a long commercialization timeline and a high cash burn.
What to watch:
- The opening gap versus the $4.46 after-hours print
- Customer sample shipments and billings
- Any new partnerships beyond Murata and Corning
Forecast: Holding $3.98 keeps $4.46 to $4.75 in reach. A fade loses $3.60.
Why this matters: QS is a battery-technology moonshot that is now trying to prove demand beyond autos, including AI data centers and defense.
6. Insteel Industries (IIIN) | Earnings Before the Open | Closed $30.39 (+0.33%)
A $570 Million Steel-Wire Maker Reports at 6:30 A.M. After an Unconfirmed 10% After-Hours Pop
Catalyst & latest news: Insteel reports fiscal Q4 on Oct. 22 at 6:30 a.m. ET with a call at 10:00 a.m. Analysts expect about $0.49 in EPS and 13.4% revenue growth. Benzinga’s after-market feed showed IIIN up 10.4% to $33.54, but StockAnalysis showed no after-hours change at 4:10 p.m., so treat that print with caution.
Technicals: StockAnalysis shows IIIN closed at $30.39 on 180,118 shares, within a $30.11 to $30.73 range. It was $29.66 on Oct. 16, and its 52-week range is $24.35 to $38.73.
Fundamentals: Fiscal Q3 revenue was $197.7M, up 9.9%, but net income fell to $9.0M from $15.2M. Management said margins should stay near current levels unless pricing improves. The stock trades near 12.5x earnings.
| Metric | Data |
|---|---|
| Last close / prior close | $30.39 (+$0.10, +0.33%) / $30.29 |
| Day’s range | $30.11 – $30.73 |
| After-hours | $30.39 (flat on StockAnalysis); $33.54 (+10.4%) on Benzinga, unconfirmed |
| 52-week range | $24.35 – $38.73 |
| Market cap | About $571M (Oct. 8) |
| P/E / Dividend | About 12.5 / n/v |
| Volume vs. average | 180K / n/v |
| Performance | 30-day +1.5%; 90-day -4.5% |
| Q3 revenue / net income | $197.7M (+9.9%) / $9.0M (vs. $15.2M) |
| Q4 estimates | EPS about $0.49; revenue growth about +13.4% |
| Analysts | Neutral (1 analyst); target $39 (+28%) |
| Next earnings | Oct. 22, 6:30 a.m. ET |
| Support (S1 / S2 / S3) | $30.11 / $29.66 / $27 |
| Resistance (R1 / R2 / R3) | $30.73 / $33.54 / $38.73 |
Scenarios:
Bullish: a beat and firm pricing push through $33.54. Base: a 4% to 7% move either way. Bearish: a margin miss breaks $29.66.
Bull case: A low multiple, rising infrastructure demand and a target 28% above the price. Bear case: Shrinking profit, a one-analyst Street and a history of volatile earnings reactions (a 61% EPS miss in April).
What to watch:
- Fiscal 2027 pricing and margin commentary
- Volume versus its normal 180K
- Any tariff or imported-wire comments
Forecast: A beat points to $33 to $34. A miss likely tests $29.66 and then $27.
Why this matters: Insteel is a small-cap read on construction and infrastructure steel demand ahead of the Fed meeting.
7. PDS Biotechnology (PDSB) | Cancer Data and Dilution | Closed $1.24 (+29.10%)
Down 44% in a Week, Then Up 29% in a Day: A Biotech Rollercoaster
Catalyst & latest news: PDSB closed at $1.24 after a Oct. 20 investor presentation highlighted a 71.4% response rate for PDS0301 in metastatic colorectal cancer versus 35% for chemotherapy alone, plus a 39.3-month median survival for PDS0101 in head and neck cancer. Morningstar showed a 34% jump to $1.27 intraday, and the stock fell 6.5% after hours to $1.16.
Technicals: PDSB closed at $1.71 on Oct. 13, slid to about $0.96 by Oct. 20 and then surged 29%. Its early-October low was near $0.71.
Fundamentals & financing: The company raised an $11.3M initial PIPE at roughly $0.28 per unit with warrants, up to $22.3M in total, and filed a securities offering registration on Oct. 14. The current ratio is about 0.6, and Patrick Soon-Shiong’s group owns at least 15%.
| Metric | Data |
|---|---|
| Last close / prior close | $1.24 (+$0.279, +29.10%) / $0.961 |
| Intraday high | About $1.27 (+34%) |
| After-hours | $1.16 (-6.45%) |
| 52-week range | n/v |
| Market cap | About $65M |
| P/E / Dividend | n/a (loss-making) / None |
| Volume vs. average | n/v |
| Performance | About -44% from Oct. 13 close to Oct. 20; +29% on Oct. 21 |
| Key data | PDS0301 mCRC response 71.4% vs. 35%; PDS0101 median survival 39.3 months |
| Liquidity | Current ratio about 0.6; $11.3M PIPE closed; offering registered Oct. 14 |
| Analysts | H.C. Wainwright Buy, $5 (cut from $7) |
| Support (S1 / S2 / S3) | $1.16 / $0.96 / $0.72 |
| Resistance (R1 / R2 / R3) | $1.27 / $1.35 / $1.71 |
Scenarios:
Bullish: a hold above $1.16 targets $1.35. Base: a gap-and-fade between $1.10 and $1.30. Bearish: a loss of $0.96 erases the move.
Bull case: Peer-reviewed survival data, an activist-style 15% holder and a Phase 3 program. Bear case: Heavy dilution, a registered offering, tight liquidity and a track record of sharp reversals.
What to watch:
- Any offering priced after the spike
- Phase 3 protocol filing timing for PDS0301
- Volume above its recent average
Forecast: Holding $1.16 keeps $1.27 to $1.35 in play. A fade under $0.96 points to $0.72.
Why this matters: PDSB captures the biotech trade-off: strong data on one side, and an offering that could cap the rally on the other.
8. American Bitcoin (ABTC) | Bitcoin Rebound Play | Last Print $8.71 (+13.4%)
A Trump-Family Miner With About 8,300 Bitcoin and a Director Buying the Dip
Catalyst & latest news: ABTC rose as much as 13% Wednesday as Bitcoin climbed to about $84,700 on SpaceX and Super Micro optimism, with spot ETFs drawing more than $549M. MarketBeat noted a midday price of $8.145 on light volume and a director purchase that lifted his stake 49%. Benzinga’s feed shows a last print of $8.71, and the official close is not verified.
Technicals: The prior close was about $7.68. ABTC sits between its 50-day ($8.32) and 200-day ($10.85) averages, with a 3.96 beta. Midday volume of 209K was 82% below its average.
Fundamentals: American Bitcoin is 80% owned by Hut 8 and holds about 8,300 BTC. It posted 2025 revenue of $185M and a $153M net loss, and it reports Q3 results in November. H.C. Wainwright called it a pure-play Bitcoin accumulation platform with a $22 target.
| Metric | Data |
|---|---|
| Last print / prior close | About $8.71 (+13.4%, intraday; close n/v) / about $7.68 (derived) |
| Midday price | $8.145 (+6.1%) |
| 52-week range | n/v |
| Market cap | About $557M – $627M |
| P/E / Dividend | About -2.8 / None |
| Volume vs. average | 209K midday vs. about 1.2M average |
| Beta | 3.96 |
| Holdings | About 8,300 BTC; 80% owned by Hut 8 |
| Revenue / net loss (2025) | $185M / -$153M |
| Analysts | 4 Buy, 1 Hold, 1 Sell; Maxim $16, H.C. Wainwright $22; average about $14.67 |
| Insiders / institutions | 2.57% / 10.21% |
| Support (S1 / S2 / S3) | $7.68 / $7 / $6.20 |
| Resistance (R1 / R2 / R3) | $8.32 (50-day) / $10.85 (200-day) / $16 |
Scenarios:
Bullish: Bitcoin holds $84,000 and ABTC clears $8.32. Base: a $7.70 to $8.70 range. Bearish: a Bitcoin reversal loses $7.68 and tests $7.
Bull case: A low-cost miner, a Bitcoin treasury, two Buy-rated targets above $15 and a director buying. Bear case: Large losses, a reverse-split history, thin liquidity and a stock that tracks Bitcoin with nearly 4x beta.
What to watch:
- Bitcoin’s response to the $85,000 level
- Q3 results and holdings update in November
- Hut 8 headlines
Forecast: A close above $8.32 targets the 200-day near $10.85. A Bitcoin pullback likely retests $7.68.
Why this matters: ABTC is a leveraged proxy for Bitcoin and AI-risk sentiment, which moved together this week.
9. Cypherpunk Technologies (CYPH) | Zcash Treasury Surge | Close About $3.33 (+18.5%, derived)
Two Straight Double-Digit Gains for a Winklevoss-Backed Zcash Play, Up 360% Since June
Catalyst & latest news: CYPH rose about 18.5% Wednesday after closing at $2.81, up 11.1%, on 11.9M shares versus a 15.8M average. The formerly biotech company holds a Zcash treasury, and a Zcash mining unit bought for $33.33M in stock produced 3,023 ZEC in its first weeks. A Form 4 filing posted Oct. 21.
Technicals: Marketchameleon shows 30-day implied volatility of 142%. CYPH has a $0.49 to $4.19 range, is up about 142% year to date and about 360% since June 30. It plunged about 40% on June 5 on a Zcash privacy-bug scare.
Fundamentals: The company held 290,063 ZEC (1.76% of supply) as of its December update and aims for 5%. Finviz shows a Cantor Overweight rating and a $4.15 target. Trailing EPS is -$6.30, and the share count has grown sharply, so check dilution.
| Metric | Data |
|---|---|
| Last close (derived) / prior close | About $3.33 (+18.5%) / $2.81 (Oct. 20, +11.1%) |
| Intraday range / high | About $2.90 – $3.41 (high per MarketBeat) |
| 52-week range | $0.49 – $4.19 |
| Market cap | n/v ($273M – $600M across sources, by share count) |
| P/E / Dividend | n/a (loss-making; EPS -$6.30) / None |
| Volume vs. average | 11.9M (Oct. 20) vs. about 15.8M |
| Implied volatility (30-day) | 142.4% |
| Performance | YTD about +142%; about +360% since June 30 |
| Treasury | 290,063 ZEC (1.76% of supply, Dec. 2025); mining unit bought for $33.33M |
| Analysts | Cantor Overweight; target $4.15 |
| Support (S1 / S2 / S3) | $2.81 / $2.48 / $1.50 |
| Resistance (R1 / R2 / R3) | $3.41 / $4.15 / $4.19 |
Scenarios:
Bullish: Zcash strength and a break of $3.41 target $4.15. Base: a pullback to $3.00 to $3.30. Bearish: a loss of $2.81 erases the two-day move.
Bull case: A crypto treasury with mining income, a Cantor Overweight rating and a Zcash rally. Bear case: A single-asset treasury, past privacy-bug scares, dilution and 142% implied volatility.
What to watch:
- Zcash and Bitcoin direction after the $84,000 rebound
- Any new ZEC purchase or mining update
- Volume versus its roughly 16M average
Forecast: A close above $3.41 targets $4.15. A loss of $2.81 likely sends the stock to $2.48.
Why this matters: CYPH shows how crypto-treasury stocks can double fast in a risk-on week, and fall as fast when sentiment turns.
10. Tenax Therapeutics (TENX) | Post-Failure Rebound Attempt | Close About $1.63 (derived)
An 85% Phase 3 Crash, a Paused Trial and a Subgroup That Will Not Go Away
Catalyst & latest news: TENX rose 8.6% to $1.77 in after-hours trading on a $40.3M market value, which implies a regular close near $1.63. The stock lost about 84% to 85% in August when its Phase 3 LEVEL trial of oral levosimendan missed its primary goal. On Oct. 8 it paused LEVEL-2 enrollment to tighten criteria and asked the FDA for a Type C meeting.
Technicals: TENX is a thinly traded micro-cap well below its pre-failure levels, and the after-hours price of $1.77 sits near a round-number resistance at $2.00. Wednesday’s catalyst is not confirmed in the sources we checked.
Fundamentals: In a more responsive subgroup (baseline six-minute walk under 333 meters), the drug improved the walk by 26.3 meters (p = 0.0112). Q2 net loss was $17.8M on $12.9M of R&D, and law firms have announced shareholder investigations.
| Metric | Data |
|---|---|
| Last close (derived) / prior close | About $1.63 / n/v |
| After-hours | $1.77 (+8.58%) |
| 52-week range / day range | n/v / n/v |
| Market cap | About $37M at the close (derived); $40.3M at $1.77 |
| P/E / Dividend | n/a (pre-revenue) / None |
| Volume vs. average | n/v |
| Performance | About -85% in a single session in August |
| Q2 net loss / R&D | $17.8M / $12.9M |
| Key data | Subgroup 6MWD +26.3 m vs. placebo (p = 0.0112); LEVEL-2 paused Oct. 8 |
| Analysts | Roth Buy, $5 (from $30); Guggenheim Buy, $4 (from $40); Chardan Neutral, $5; William Blair Market Perform |
| Support (S1 / S2 / S3) | $1.50 / $1.30 / $1.00 |
| Resistance (R1 / R2 / R3) | $1.77 / $2.00 / $2.50 |
Scenarios:
Bullish: an FDA meeting update or LEVEL-2 restart lifts the stock through $2.00. Base: a bounce-and-fade near $1.60 to $1.80. Bearish: a loss of $1.50 reopens $1.30. Support and resistance are round-number zones because verified daily data was limited.
Bull case: A positive subgroup result, a valuation of about $40M and analyst targets of $4 to $5. Bear case: The pivotal trial failed, enrollment is paused, cash burn continues and legal investigations are open.
What to watch:
- Any FDA Type C meeting outcome
- LEVEL-2 enrollment restart timing
- Cash runway and financing news
Forecast: Holding $1.50 allows a test of $2.00. A loss of $1.50 points to $1.30.
Why this matters: TENX is a classic post-failure biotech where a regulatory update can move the stock 30% in either direction.
Sector Sentiment Snapshot and Forecast
| Group | Names | Sentiment | Driver |
|---|---|---|---|
| AI power and optical | BE, MXL | Event-driven | Oct. 22 earnings after the close, 9% to 12% implied moves |
| Industrial and aerospace | HXL, IIIN | Cautious | Revenue miss, steel pricing and margins |
| Tech hardware and batteries | NVEC, QS | Mixed | Earnings gaps in both directions |
| Biotech | PDSB, TENX | Speculative | Data, financing and FDA process |
| Crypto-linked | ABTC, CYPH | Risk-on | Bitcoin near $85,000 |
Sector forecast: Thursday opens with P&G, Valero, Union Pacific and Lockheed before the bell, then Intel, Western Digital and Bloom Energy after it. After-hours selling in Lam Research and gains in Meta suggest the market is rewarding revenue guidance and punishing misses, which favors Bloom and MaxLinear only if they raise outlooks. Crypto-linked and micro-cap biotech names are rallying with Bitcoin and risk appetite, but they carry dilution risk, and the Fed meets Oct. 27-28. For broader setups, see TNN’s Oct. 13 top 10 stocks and Oct. 14 stocks to watch.
Stocks to Watch Tomorrow: At a Glance
| # | Stock | Last Close | Move | Catalyst | Key Support | Key Resistance |
|---|---|---|---|---|---|---|
| 1 | BE | $238.53 | +7.13% (AH about -2%) | Q3 earnings after close | $229.30 | $243 |
| 2 | MXL | $75.79 (reading) | +3.1% | Q3 earnings after close | $73.22 | $77.17 |
| 3 | HXL | About $89.84 | -1.58% (AH about -10%) | Revenue miss | $79.82 | $89.84 |
| 4 | NVEC | $103.07 | +1.00% (AH about -19% to -21%) | Earnings, defense sales -95% | $81.27 | $90 |
| 5 | QS | About $3.98 | AH +12.1% | Q3 loss smaller than expected | $3.98 | $4.46 |
| 6 | IIIN | $30.39 | +0.33% | Q4 earnings, 6:30 a.m. | $30.11 | $30.73 |
| 7 | PDSB | $1.24 | +29.10% | Cancer data, offering | $1.16 | $1.27 |
| 8 | ABTC | About $8.71 | About +13.4% | Bitcoin rebound | $7.68 | $8.32 |
| 9 | CYPH | About $3.33 | About +18.5% | Zcash treasury rally | $2.81 | $3.41 |
| 10 | TENX | About $1.63 | AH +8.6% | Post-failure rebound | $1.50 | $1.77 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, micro-cap, event-driven and high-volatility stocks carry elevated risk, including dilution, delisting and total loss. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. After-hours prices are indicative, and some closes are derived or unverified and labeled as such. Support and resistance levels are analytical zones, not predictions. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
